GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hemogenyx Pharmaceuticals HEMO.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

565.00p

-0.88%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hemogenyx Pharmaceuticals

Its shares trade on LSE under the ticker HEMO.L. It has been listed since 9 November 2015.

HemoGenyx Pharmaceuticals Plc operates as a biopharmaceutical company, which engages in the development of novel therapies to transform bone marrow and blood stem cell transplantation. The firm is focused on developing new treatments for blood diseases such as leukaemia, lymphoma and blood marrow failure. Its therapies are designed to provide new treatments in bone marrow/stem cell transplants, improving the success and safety of such treatments. Its products include Conditioning and Cell therapy product. Conditioning product is for CDX bi-specific antibodies, redirects a patient’s own immune cells to eliminate unwanted blood stem cells preparing a patient for bone marrow (also known as haematopoietic stem cell) transplantation. Cell therapy product uses human postnatal hemogenic endothelial cells (HuPHECs) to generate cancer-free, patient-matched blood stem cells after transplant into the patient.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
9 Nov 2015
Employees
7

Leadership

Pay as last reported

  • Prof. Marc FeldmannNon-Executive Chairman of the Board£49,000
  • Dr. Vladislav SandlerChief Executive Officer, Co-Founder, Executive Director, since 2017£445,000
  • Mr. Peter RedmondIndependent Non-Executive Director£58,000
  • Ms. Alexis SandlerIndependent Non-Executive Director£60,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • HemoGenyx focuses on innovative biopharmaceutical therapies for blood diseases like leukaemia and lymphoma.
  • The company develops CDX bi-specific antibodies for conditioning in stem cell transplants.
  • HuPHECs technology generates cancer-free, patient-matched blood stem cells post-transplant.

Weaknesses

  • HemoGenyx has only 7 employees, limiting operational capacity.
  • The company is listed in London with a small team size.
  • Limited workforce may hinder rapid product development and market expansion.

Opportunities

  • Growing demand for advanced stem cell therapies in the Health Care sector.
  • Expanding applications for CDX bi-specific antibodies in blood disease treatment.
  • Potential market growth in Europe for biopharmaceutical innovations.

Threats

  • Competition from larger biotech firms in the Health Care industry.
  • Regulatory challenges in developing novel biopharmaceutical therapies.
  • High costs associated with clinical trials for new treatments.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.